Search

Your search keyword '"Davis, Ian"' showing total 3,164 results
Start Over Author "Davis, Ian"
3,164 results on '"Davis, Ian"'

1. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

Author

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M., Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Ravi Kumar, Aravind S., Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, McJannett, Margaret, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S., Martin, Andrew J., Davis, Ian D., Stockler, Martin R., Zebic, Danka, Mak, Blossom, Tankard, Nicole, Rana, Nisha, Cusick, Thomas, Thompson, Jennifer, Oakes, Samantha, Niu, Claire, Thein, Thida, Ford, Kate, Ristevski, Nikola, Yip, Sonia, Bills, Madison, Joshua, Anthony M, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Kirkwood, Ian D, Rutherford, Natalie K, Kumar, Aravind S Ravi, Nadebaum, David P, Redfern, Andrew D, Hofman, Michael S, Martin, Andrew James, Davis, Ian D, and Stockler, Martin R

Published
2025
Full Text
View/download PDF

4. SCARLET (Supplemental Citicoline Administration to Reduce Lung injury Efficacy Trial): study protocol for a single-site, double-blinded, placebo-controlled, and randomized Phase 1/2 trial of i.v. citicoline (CDP-choline) in hospitalized SARS CoV-2-infected patients with hypoxemic acute respiratory failure

Author

Pannu, Sonal, Exline, Matthew C., Bednash, Joseph S., Englert, Joshua A., Diaz, Philip, Bartlett, Amy, Brock, Guy, Wu, Qing, Davis, Ian C., and Crouser, Elliott D.

Published
2024
Full Text
View/download PDF

7. Preventing Respiratory Viral Illness Invisibly (PRiVII): protocol for a pragmatic cluster randomized trial evaluating far-UVC light devices in long-term care facilities to reduce infections

Author

Nix, Hayden P., Meeker, Samantha, King, Caroline E., Andrew, Melissa, Davis, Ian R. C., Koto, Prosper S., Sim, Meaghan, Murdoch, Jennifer, Patriquin, Glenn, Theriault, Chris, Reidy, Stephanie, Rockwood, Michael, Sampalli, Tara, Searle, Samuel D., and Rockwood, Kenneth

Published
2024
Full Text
View/download PDF

8. In Situ Structural Observation of a Substrate- and Peroxide-Bound High-Spin Ferric-Hydroperoxo Intermediate in the P450 Enzyme CYP121

Author

Nguyen, Romie C, Davis, Ian, Dasgupta, Medhanjali, Wang, Yifan, Simon, Philipp S, Butryn, Agata, Makita, Hiroki, Bogacz, Isabel, Dornevil, Kednerlin, Aller, Pierre, Bhowmick, Asmit, Chatterjee, Ruchira, Kim, In-Sik, Zhou, Tiankun, Mendez, Derek, Paley, Daniel W, Fuller, Franklin, Mori, Roberto Alonso, Batyuk, Alexander, Sauter, Nicholas K, Brewster, Aaron S, Orville, Allen M, Yachandra, Vittal K, Yano, Junko, Kern, Jan F, and Liu, Aimin

Subjects
Inorganic Chemistry, Chemical Sciences, Bioengineering, Good Health and Well Being, Peroxides, Peracetic Acid, Ligands, Cytochrome P-450 Enzyme System, Iron, Heme, Tyrosine, Carbon, General Chemistry, Chemical sciences, Engineering
Abstract

The P450 enzyme CYP121 from Mycobacterium tuberculosis catalyzes a carbon-carbon (C-C) bond coupling cyclization of the dityrosine substrate containing a diketopiperazine ring, cyclo(l-tyrosine-l-tyrosine) (cYY). An unusual high-spin (S = 5/2) ferric intermediate maximizes its population in less than 5 ms in the rapid freeze-quenching study of CYP121 during the shunt reaction with peracetic acid or hydrogen peroxide in acetic acid solution. We show that this intermediate can also be observed in the crystalline state by EPR spectroscopy. By developing an on-demand-rapid-mixing method for time-resolved serial femtosecond crystallography with X-ray free-electron laser (tr-SFX-XFEL) technology covering the millisecond time domain and without freezing, we structurally monitored the reaction in situ at room temperature. After a 200 ms peracetic acid reaction with the cocrystallized enzyme-substrate microcrystal slurry, a ferric-hydroperoxo intermediate is observed, and its structure is determined at 1.85 Å resolution. The structure shows a hydroperoxyl ligand between the heme and the native substrate, cYY. The oxygen atoms of the hydroperoxo are 2.5 and 3.2 Å from the iron ion. The end-on binding ligand adopts a near-side-on geometry and is weakly associated with the iron ion, causing the unusual high-spin state. This compound 0 intermediate, spectroscopically and structurally observed during the catalytic shunt pathway, reveals a unique binding mode that deviates from the end-on compound 0 intermediates in other heme enzymes. The hydroperoxyl ligand is only 2.9 Å from the bound cYY, suggesting an active oxidant role of the intermediate for direct substrate oxidation in the nonhydroxylation C-C bond coupling chemistry.

Published
2023

9. Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

Author

Gafita, Andrei, Martin, Andrew J., Emmett, Louise, Eiber, Matthias, Iravani, Amir, Fendler, Wolfgang P., Buteau, James, Sandhu, Shahneen, Azad, Arun A., Herrmann, Ken, Stockler, Martin R., Davis, Ian D., and Hofman, Michael S.

Published
2025
Full Text
View/download PDF

10. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Author

Gillessen, Silke, Turco, Fabio, Davis, Ian D., Efstathiou, Jason A., Fizazi, Karim, James, Nicholas D., Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Zilli, Thomas, Agarwal, Neeraj, Antonarakis, Emmanuel S., Aparicio, Ana, Armstrong, Andrew J., Bastos, Diogo Assed, Attard, Gerhardt, Axcrona, Karol, Ayadi, Mouna, Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Bourlon, Maria T., Briganti, Alberto, Bulbul, Muhammad, Buttigliero, Consuelo, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Clarke, Caroline S., Clarke, Noel, de Bono, Johann S., De Santis, Maria, Duran, Ignacio, Efstathiou, Eleni, Ekeke, Onyeanunam N., El Nahas, Tamer I.H., Emmett, Louise, Fanti, Stefano, Fatiregun, Omolara A., Feng, Felix Y., Fong, Peter C.C., Fonteyne, Valerie, Fossati, Nicola, George, Daniel J., Gleave, Martin E., Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Hofman, Michael S., Hope, Thomas A., Horvath, Lisa G., Hussain, Maha H.A., Jereczek-Fossa, Barbara Alicja, Jones, Robert J., Joshua, Anthony M., Kanesvaran, Ravindren, Keizman, Daniel, Khauli, Raja B., Kramer, Gero, Loeb, Stacy, Mahal, Brandon A., Maluf, Fernando C., Mateo, Joaquin, Matheson, David, Matikainen, Mika P., McDermott, Ray, McKay, Rana R., Mehra, Niven, Merseburger, Axel S., Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Mutambirwa, Shingai B.A., Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M, Rathkopf, Dana, Reiter, Robert E., Renard-Penna, Raphaele, Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sandhu, Shahneen, Sartor, Oliver A., Schaeffer, Edward, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona A., Soule, Howard R., Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Suzuki, Hiroyoshi, Taplin, Mary-Ellen, Thellenberg-Karlsson, Camilla, Tilki, Derya, Türkeri, Levent N., Uemura, Hiroji, Ürün, Yüksel, Vale, Claire L., Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, and Omlin, Aurelius

Published
2025
Full Text
View/download PDF

11. Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial

Author

Allegretti, Jessica R., Kelly, Colleen R., Louie, Thomas, Fischer, Monika, Hota, Susy, Misra, Bharat, Van Hise, Nick W., Yen, Eugene, Bullock, Jeffrey S., Silverman, Michael, Davis, Ian, McGill, Sarah K., Pardi, Darrell S., Orenstein, Robert, Grinspan, Ari, El-Nachef, Najwa, Feuerstadt, Paul, Borody, Thomas J., Khanna, Sahil, Budree, Shrish, and Kassam, Zain

Published
2025
Full Text
View/download PDF

12. NATO and missile defence

Author

Davis, Ian

Subjects
MISSILE DEFENSE, AIR DEFENSES - North Atlantic Treaty Organization, ROLES AND MISSIONS - North Atlantic Treaty Organization
Abstract

illus chart

Published
2005

13. Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report

Author

Meade, Angela, Frangou, Elena, Choodari-Oskooei, Babak, Larkin, James, Powles, Tom, Stewart, Grant D., Albiges, Laurence, Bex, Axel, Choueiri, Toni K., Davis, Ian D., Eisen, Tim, Fielding, Alison, Gedye, Craig, Harrison, David J., Kaplan, Rick, Mulhere, Salena, Nathan, Paul, Patel, Grisma, Patel, Jay, Plant, Hannah, Ritchie, Alastair, Rush, Hannah, Shakeshaft, Clare, Stockler, Martin R., Suarez, Cristina, Thompson, Jemima, Thorogood, Nat, Venugopal, Balaji, and Parmar, Mahesh K.B.

Published
2024
Full Text
View/download PDF

17. Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance

Author

Sharifi, Nima, Diaz, Robert, Lin, Hui-Ming, Roberts, Evan, Horvath, Lisa G., Martin, Andrew, Stockler, Martin R., Yip, Sonia, Subhash, Vinod V., Portman, Neil, Davis, Ian D., and Sweeney, Christopher J.

Subjects
Physiological aspects, Genetic aspects, Prognosis, Health aspects, Epigenetic inheritance -- Health aspects, Men's health -- Genetic aspects, Hormones -- Health aspects, Medical research, Prostate cancer -- Physiological aspects -- Prognosis, Cancer metastasis -- Physiological aspects, Medicine, Experimental, Metastasis -- Physiological aspects, Men -- Health aspects
Abstract

Introduction Prostate cancer has long been recognized to be an androgen-dependent disease, with some cancers being more dependent than others. Androgen deprivation therapy (ADT) with gonadal testosterone suppression has therefore [...], BACKGROUND. Metastatic hormone-sensitive prostate cancer (mHSPC) is androgen dependent, and its treatment includes androgen deprivation therapy (ADT) with gonadal testosterone suppression. Since 2014, overall survival (OS) has been prolonged with addition of other systemic therapies, such as adrenal androgen synthesis blockers, potent androgen receptor blockers, or docetaxel, to ADT. HSD3B1 encodes the rate-limiting enzyme for nongonadal androgen synthesis, 3[beta]-hydroxysteroid dehydrogenase-1, and has a common adrenal-permissive missense-encoding variant that confers increased synthesis of potent androgens from nongonadal precursor steroids and poorer prostate cancer outcomes. METHODS. Our prespecified hypothesis was that poor outcome associated with inheritance of the adrenal-permissive HSD3B1 allele with ADT alone is reversed in patients with low-volume (LV) mHSPC with up-front ADT plus addition of androgen receptor (AR) antagonists to inhibit the effect of adrenal androgens. HSD3B1 genotype was obtained in 287 patients with LV disease treated with ADT + AR antagonist only in the phase III Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET) trial and was associated with clinical outcomes. RESULTS. Patients who inherited the adrenal-permissive HSD3B1 allele had more favorable 5-year clinical progression-free survival and OS when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen compared with their counterparts who did not have adrenal-permissive HSD3B1 inheritance. HSD3B1 was also associated with OS after accounting for known clinical variables. Patients with both genotypes benefited from early enzalutamide. CONCLUSION. These data demonstrated an inherited physiologic driver of prostate cancer mortality is associated with clinical outcomes and is potentially pharmacologically reversible. FUNDING. National Cancer Institute, NIH; Department of Defense; Prostate Cancer Foundation, Australian National Health and Medical Research Council.

Published
2024
Full Text
View/download PDF

20. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)

Author

Weickhardt, Andrew, Foroudi, Farshad, Lawrentschuk, Nathan, Xie, Jing, Sidhom, Mark, Pal, Abhijit, Grimison, Peter, Zhang, Alison, Ng, Siobhan, Tang, Colin, Hovey, Elizabeth, Chen, Colin, Hruby, George, Guminski, Alexander, McJannett, Margaret, Conduit, Ciara, Tran, Ben, Davis, Ian D., and Hayne, Dickon

Published
2024
Full Text
View/download PDF

21. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Author

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, and Davis, Ian D

Published
2024
Full Text
View/download PDF

23. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

Author

Galsky, Matthew D., Guan, Xiangnan, Rishipathak, Deepali, Rapaport, Aaron S., Shehata, Hesham M., Banchereau, Romain, Yuen, Kobe, Varfolomeev, Eugene, Hu, Ruozhen, Han, Chia-Jung, Li, Haocheng, Liang, Yuxin, Vucic, Domagoj, Wang, Li, Zhu, Jun, Yu, Haocheng, Herbst, Rebecca H., Hajaj, Emma, Kiner, Evgeny, Bamias, Aristotelis, De Santis, Maria, Davis, Ian D., Arranz, José Ángel, Kikuchi, Eiji, Bernhard, Sandrine, Williams, Patrick, Lee, Chooi, Mellman, Ira, Sanjabi, Shomyseh, Johnston, Robert, Black, Peter C., Grande, Enrique, and Mariathasan, Sanjeev

Published
2024
Full Text
View/download PDF

24. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Author

Grande, Enrique, Arranz, José Á, De Santis, Maria, Bamias, Aristotelis, Kikuchi, Eiji, del Muro, Xavier Garcia, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Schutz, Fabio A, Puente, Javier, Li, Jian-Ri, O'Donnell, Peter H, Kalebasty, Arash Rezazadeh, Ye, Dingwei, Mariathasan, Sanjeev, Bene-Tchaleu, FabioIa, Bernhard, Sandrine, Lee, Chooi, Davis, Ian D, and Galsky, Matthew D

Published
2024
Full Text
View/download PDF

25. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Author

Bamias, Aristotelis, Davis, Ian D, Galsky, Matthew D, Arranz, José Á, Kikuchi, Eiji, Grande, Enrique, del Muro, Xavier Garcia, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Schutz, Fabio A, Puente, Javier, Li, Jian-Ri, Panni, Stefano, Gumus, Mahmut, Özgüroğlu, Mustafa, Mariathasan, Sanjeev, Poloz, Yekaterina, Bene-Tchaleu, Fabiola, Lee, Chooi, Bernhard, Sandrine, and De Santis, Maria

Published
2024
Full Text
View/download PDF

26. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Bailey, Dale, Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Crumbaker, Megan, Dhiantravan, Nattakorn, Hamid, Anis, Haskali, Mohammad, Hung, Terry, Kong, Grace, Lawrence, Nick, Lewin, Jeremy, McCarthy, Michael, Moodie, Kate, Murphy, Declan, Nguyen, Andrew, Pook, David, Ravi Kumar, Aravind, Roach, Paul, Roselt, Peter, Saghebi, Javad, Schembri, Geoff, Spain, Lavinia, Subramaniam, Shalini, Thang, Sue Ping, Thomas, Paul, Tran, Ben, Wallace, Roslyn, Yip, Sonia, Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, and Davis, Ian D

Published
2024
Full Text
View/download PDF

28. Music as a Single Entity

Author

Davis, Ian

Subjects
Composers, Arts, visual and performing, Regional focus/area studies
Abstract

LUBOS MRKVICKA HAS BEEN A STRONG PRESENCE ON THE CZECH COMPOSITIONAL SCENE FOR MANY YEARS, BOTH AS AN ACTIVE COMPOSER AND AS A PEDAGOGUE. HIS MUSIC AND COMPOSITIONAL APPROACH HAVE [...]

Published
2023

30. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Author

Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Chi, Kim N, Clarke, Noel, Davis, Ian D, de Bono, Johann, Drake, Charles G, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Heinrich, Daniel, Higano, Celestia Tia S, Hofman, Michael S, Hussain, Maha, James, Nicolas, Kanesvaran, Ravindran, Kantoff, Philip, Khauli, Raja B, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Chris, Poon, Darren MC, Pritchard, Colin C, Reiter, Robert E, Roach, Mack, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Small, Eric, Smith, Matthew, Soule, Howard, Sternberg, Cora N, Steuber, Thomas, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tombal, Bertrand, Türkeri, Levent, van Oort, Inge, Zapatero, Almudena, and Omlin, Aurelius

Subjects
Cancer, Urologic Diseases, Aging, Prostate Cancer, Good Health and Well Being, Bone Neoplasms, Humans, Male, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Practice Guidelines as Topic, Prostate-Specific Antigen, Prostatic Neoplasms, Advanced prostate cancer, High-risk localised prostate cancer, Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Oligometastatic prostate cancer, Progression-free survival, Overall survival, Prostate cancer treatment, Imaging, Genetics, Tumour genomic profiling, Castration-naïve prostate cancer, Clinical Sciences, Urology & Nephrology
Abstract

BackgroundInnovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.ObjectiveTo present the results from the APCCC 2019.Design, setting, and participantsSimilar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions.Outcome measurements and statistical analysisThe panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process.Results and limitationsPanellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material.ConclusionsThese voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials.Patient summaryThe Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.

Published
2020

31. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

33. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

35. Unsupervised Anomalous Data Space Specification

Author

Davis, Ian J

Subjects
Computer Science - Machine Learning, Statistics - Machine Learning
Abstract

Computer algorithms are written with the intent that when run they perform a useful function. Typically any information obtained is unknown until the algorithm is run. However, if the behavior of an algorithm can be fully described by precomputing just once how this algorithm will respond when executed on any input, this precomputed result provides a complete specification for all solutions in the problem domain. We apply this idea to a previous anomaly detection algorithm, and in doing so transform it from one that merely detects individual anomalies when asked to discover potentially anomalous values, into an algorithm also capable of generating a complete specification for those values it would deem to be anomalous. This specification is derived by examining no more than a small training data, can be obtained in very small constant time, and is inherently far more useful than results obtained by repeated execution of this tool. For example, armed with such a specification one can ask how close an anomaly is to being deemed normal, and can validate this answer not by exhaustively testing the algorithm but by examining if the specification so generated is indeed correct. This powerful idea can be applied to any algorithm whose runtime behavior can be recovered from its construction and so has wide applicability., Comment: 18 Pages

Published
2018

37. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Tomczak, Piotr, Choueiri, Toni, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas R., Hajek, Jaroslav, Lin, Tzu-Ping, Symeonides, Stefan N., Lee, Jae Lyun, Sawrycki, Piotr, Haas, Naomi B., Gurney, Howard P., Mahave, Mauricio, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Chevreau, Christine, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Topart, Delphine, Oudard, Stephane, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Quinn, David I., Alva, Ajjai, Menezes, Juliana de Janoski, Silva, Adriano Goncalves e, Winquist, Eric W., Hamzaj, Alketa, Procopio, Giuseppe, Karaszewska, Boguslawa, Nowakowska-Zajdel, Ewa M., Alekseev, Boris Y., Gafanov, Rustem A., Izmailov, Adel, Semenov, Andrey, Afanasyev, Sergey G., Lipatov, Oleg N., Powles, Thomas B., Srinivas, Sandy, McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Chung, Jinsoo, Shkolnik, Michail I., Matveev, Vsevolod B., Gajate Borau, Pablo, McCune, Steven, Hutson, Thomas E., Dri, Alejandro, Sales, Silvio Correia, Yeung, Carrie, Alcala Castro, Carmen Marcela, Bostrom, Peter, Laguerre, Brigitte, Buttigliero, Consuelo, de Giorgi, Ugo, Fomin, Eugeniy A., Zakharia, Yousef, Hwang, Clara, Singer, Eric A., Yorio, Jeffrey T., Waterhouse, David, Kowalyszyn, Ruben Dario, Alfie, Margarita Sonia, Yanez Ruiz, Eduardo, Buchler, Tomas, Kankaanranta, Krista, Ferretti, Gianluigi, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Tamada, Satoshi, Kato, Haruaki, Kitamura, Hiroshi, Danielewicz, Iwona, Wojcik-Tomaszewska, Joanna, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Rojas-Uribe, Gustavo Adolfo, Gonzalez Fernandez, Manuel Enrique, Feyerabend, Susan, Pignata, Sandro, Numakura, Kazuyuki, Cybulska Stopa, Bozena, Zukov, Ruslan, Climent Duran, Miguel Angel, Maroto Rey, Pablo Jose, Montesa Pino, Alvaro, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Cobb, Patrick W., Hauke, Ralph, Anderson, Daniel M., Sarantopoulos, John, Gourdin, Theodore, Zhang, Tian, Jayram, Gautam, Fein, Luis Enrique, Harris, Carole, Beato, Patricia Medeiros Milhomem, Flores, Francisco, Estay, Angela, Rubiano, Juan Andres, Bedke, Jens, Hauser, Stefan, Neisius, Andreas, Busch, Jonas, Anai, Satoshi, Tsunemori, Hiroyuki, Sawka, Dariusz, Sikora-Kupis, Bozena, Arranz, Jose Angel, Delgado, Ignacio, Chen, Chung-Hsin, Gunderson, Elizabeth, Tykodi, Scott, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Kaen, Diego Lucas, Sade, Juan Pablo, Tatangelo, Marcelo Daniel, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Marceau, Daniele, Paradis, Jean-Benoit, Hanna, Nawar, Acevedo, Alejandro, Ibanez, Carolina, Villanueva, Luis, Galaz, Pedro Pablo, Durango, Isabel Cristina, Manneh, Ray, Kral, Zdenek, Holeckova, Petra, Hakkarainen, Heikki, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Tartas, Sophie, Goebell, Peter J., Grimm, Marc-Oliver, Hoefner, Thomas, Wirth, Manfred, Panic, Andrej, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Mizuno, Ryuichi, Uemura, Hirotsugu, Eto, Masatoshi, Tsujihata, Masao, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Hamberg, Paul, Marczewska-Skrodzka, Malgorzata, Szczylik, Cezary, Humphreys, Alison C., Jiang, Peter, Kumar, Birendra, Lu, Gary, Desai, Arpita, Karam, Jose Antonio, Keogh, George, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Mendez, Guillermo Ariel, Harris, Samuel J., Brown, Stephen J., Antonio Junior, Joao Neif, Costamilan, Rita de Cassia, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Lalani, Aly-Khan, Graham, Jeffrey, Levesque, Michael, Orlandi, Francisco, Kotasek, Rostislav, Deville, Jean L., Borchiellini, Delphine, Merseburger, Axel, Rink, Michael, Roos, Frederik, McDermott, Ray, Oyama, Masafumi, Yamamoto, Yoshiaki, Tomita, Yoshihiko, Miura, Yuji, Ioritani, Naomasa, Westgeest, Hans, Kubiatowski, Tomasz, Bal, Wieslaw, Girones Sarrio, Regina, Rowe, Julie, Prow, Debra M., Senecal, Francis, Hashemi-Sadraei, Neda, Cole, Scott W., Kendall, Stephan D., Richards, Donald A., Schnadig, Ian D., Gupta, Mukul, Powles, Thomas, Ferguson, Thomas, Symeonides, Stefan N, Gurney, Howard, Chang, Yen-Hwa, Haas, Naomi B, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Quinn, David I, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

39. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, Silke, Armstrong, Andrew, Attard, Gert, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Robert G., Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Clarke, Caroline S., Clarke, Noel, Davis, Ian D., de Bono, Johann S., Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celesta, Hofman, Michael S., Hussain, Maha, James, Nick, Jones, Robert, Kanesvaran, Ravindran, Khauli, Raja B., Klotz, Laurence, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Rob E., Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan P., Sartor, Oliver, Scher, Howard I., Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E., Sternberg, Cora N., Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, and Omlin, Aurelius

Published
2022
Full Text
View/download PDF

41. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).

Author

Fisher, David John, Vale, Claire Louise, Rydzewska, Larysa H, Godolphin, Peter, Agarwal, Neeraj, Attard, Gerhardt, Chi, Kim N., Clarke, Noel W, Davis, Ian D., Fizazi, Karim, Gillessen, Silke, James, Nicholas David, Matheson, David John, Oldroyd, Robert, Parmar, Mahesh K. B., Sweeney, Christopher, Tombal, Bertrand F., White, Ian R, and Tierney, Jayne F.

Published
2025
Full Text
View/download PDF

42. Overall survival and quality of life with [ 177 Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).

Author

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Sandhu, Shahneen, Zhang, Alison Yan, Hofman, Michael S., Thomas, Hayley, Martin, Andrew James, Davis, Ian D., and Stockler, Martin R

Published
2025
Full Text
View/download PDF

43. Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.

Author

Armstrong, Andrew J., Azad, Arun A., Conduit, Ciara, Haas, Gabriel P., Bland, Christopher, and Davis, Ian D.

Abstract

What is this summary about? This summary includes information from the ARCHES and ENZAMET follow-up studies. Both studies looked at enzalutamide treatment for people with metastatic hormone-sensitive prostate cancer (known as mHSPC). In ARCHES, researchers compared the medications enzalutamide + androgen deprivation therapy (known as ADT) with placebo + ADT. In ENZAMET, researchers compared enzalutamide + ADT with standard treatment + ADT. Some people in ENZAMET also took enzalutamide with docetaxel (a chemotherapy treatment). In both studies, researchers wanted to find out if enzalutamide helps people with mHSPC live longer. What are the key takeaways? In both studies, researchers found that people with mHSPC who took enzalutamide lived longer than people who did not. People who took enzalutamide also lived longer without their cancer getting worse. The results were mostly similar in groups of people dependingon when and where their cancer was found. Researchers did not find any new safety concerns. What were the main conclusions? People with mHSPC may benefit from long-term treatment with enzalutamide + ADT. They may also benefit from taking enzalutamide with other treatments, like docetaxel. It may be better for people with mHSPC to have enzalutamide treatment before their cancer gets worse, rather than waiting. These people and their doctors should carefully consider the benefits and risks of each treatment to make a joint decision for treating mHSPC. Clinical Trial Registration:NCT02677896 (ARCHES), NCT02446405 (ENZAMET) (ClinicalTrials.gov) [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

44. Characterization of Healthcare Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada,2015-2019

Author

Du, Tim, Choi, Kelly B., Silva, Anada, Golding, George R., Pelude, Linda, Hizon, Romeo, Rawahi, Ghada N. Al-, Brooks, James, Chow, Blanda, Collet, Jun C., Comeau, Jeannette L., Davis, Ian, Evans, Gerald A., Frenette, Charles, Han, Guanghong, Johnstone, Jennie, Kibsey, Pamela, Katz, Kevin C., Langley, Joanne M., Lee, Bonita E., Longtin, Yves, Mertz, Dominik, Minion, Jessica, Science, Michelle, Srigley, Jocelyn A., Stagg, Paula, Suh, Kathryn N., Thampi, Nisha, Wong, Alice, and Hota, Susy S.

Subjects
Statistics, Risk factors, Patient outcomes, Cross infection -- Statistics -- Risk factors -- Patient outcomes, Clostridium infections -- Statistics -- Risk factors -- Patient outcomes, Community-acquired infections -- Statistics -- Risk factors -- Patient outcomes, Nosocomial infections -- Statistics -- Risk factors -- Patient outcomes
Abstract

Clostridioides difficile is a major cause of infectious nosocomial diarrhea in high-income countries (1). Disease severity ranges from asymptomatic colonization to fulminant colitis, sometimes leading to colectomy and death (2). [...]

Published
2022
Full Text
View/download PDF

47. Genomes from bacteria associated with the canine oral cavity: A test case for automated genome-based taxonomic assignment.

Author

Coil, David A, Jospin, Guillaume, Darling, Aaron E, Wallis, Corrin, Davis, Ian J, Harris, Stephen, Eisen, Jonathan A, Holcombe, Lucy J, and O'Flynn, Ciaran

Subjects
Mouth, Animals, Dogs, Bacteria, DNA, Bacterial, RNA, Ribosomal, 16S, Sequence Analysis, DNA, Phylogeny, Genome, Bacterial, DNA Barcoding, Taxonomic, Whole Genome Sequencing, DNA, Bacterial, RNA, Ribosomal, 16S, Sequence Analysis, Genome, DNA Barcoding, Taxonomic, General Science & Technology
Abstract

Taxonomy for bacterial isolates is commonly assigned via sequence analysis. However, the most common sequence-based approaches (e.g. 16S rRNA gene-based phylogeny or whole genome comparisons) are still labor intensive and subjective to varying degrees. Here we present a set of 33 bacterial genomes, isolated from the canine oral cavity. Taxonomy of these isolates was first assigned by PCR amplification of the 16S rRNA gene, Sanger sequencing, and taxonomy assignment using BLAST. After genome sequencing, taxonomy was revisited through a manual process using a combination of average nucleotide identity (ANI), concatenated marker gene phylogenies, and 16S rRNA gene phylogenies. This taxonomy was then compared to the automated taxonomic assignment given by the recently proposed Genome Taxonomy Database (GTDB). We found the results of all three methods to be similar (25 out of the 33 had matching genera), but the GTDB approach required fewer subjective decisions, and required far less labor. The primary differences in the non-identical taxonomic assignments involved cases where GTDB has proposed taxonomic revisions.

Published
2019

49. Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma

Author

Giles, Graham, White, Victoria, Coory, Michael, Millar, Jeremy, Bolton, Damien, Davis, Ian, Winship, Ingrid, Roos, Ian, Southey, Melissa, Severi, Gianlucca, Prince, Miles, Harrison, Simon, Seymour, John, Jefford, Michael, Hill, David, Kay, Anne, Ellis, Robert J., White, Victoria M., Bolton, Damien M., Coory, Michael D., Davis, Ian D., Francis, Ross S., Giles, Graham G., Gobe, Glenda C., Marco, David J.T., Neale, Rachel E., Wood, Simon T., and Jordan, Susan J.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results